Sernova Appoints Ross Haghighat as New Chair and Rebrands to Sernova Biotherapeutics

Sernova Biotherapeutics has announced the appointment of Ross Haghighat as the new Chair of the Board, reflecting a strategic move to leverage his extensive experience in biotechnology and life sciences to advance their innovative bio-hybrid organ solutions. With over thirty years of experience in the healthcare sector, Haghighat's appointment is a significant step for Sernova, particularly as they pivot towards further developing their proprietary Cell Pouch technology. Furthermore, Sernova emphasizes its commitment to its corporate evolution by transitioning its legal jurisdiction to British Columbia and adopting a new company name which better reflects its biotechnology focus. The company's ongoing efforts are also focused on achieving regulatory approval for its cell therapy solution which seeks to address chronic conditions like Type 1 diabetes, employing a unique combination of bioengineering and regenerative medicine.